ClinicalTrials.gg
RecruitingNCT07947056PRaCTISe-HRUpdated Nov 18, 2026

A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin

A Phase 3 interventional study of Standard 6-month treatment regimen and High dose Rifampicin (25mg/Kg) in Tuberculosis, Pulmonary, Drug Sensitive, sponsored by Tuberculosis Research Centre, India. Recruiting at 15 sites in India. Open to participants aged 14 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionTuberculosis, PulmonaryRegistry: TuberculosisReclassifiedWhy we changed it
Registry
Tuberculosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Tuberculosis, Pulmonary
Why
  1. The study's listed conditions name Tuberculosis, Pulmonary, a narrower term within Tuberculosis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Tuberculosis Research Centre, India · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jun 2026, registered Nov 2026).
  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,500
Allocation
Randomized
Ages
14 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies testing rifampin in Tuberculosis, Pulmonary — 3 open to participants now, 3 under way, 2 of them phase 3. Rifampin · Tuberculosis, Pulmonary.

Planned enrollment
Largest of 19
2,500 · median 134
Started
2026
the only one that year
Phase 3
4 of 19
2 open now
Registered
19th of 19
by date

Among the 19 studies testing rifampin in Tuberculosis, Pulmonary, this one has the largest planned enrollment, is the only one that started in 2026, is one of 4 in phase 3, and was the 19th registered.

Tuberculosis, Pulmonary

320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.

Browse Tuberculosis, Pulmonary studies →

Open to participants now

3 of the 19 studies testing rifampin in Tuberculosis, Pulmonary are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About rifampin

Rifampin: first FDA approval 1971 (RIFADIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Tuberculosis, Pulmonary studies recruiting now, 22 (47%) set no upper age limit and 21 (45%) stop at 75 or younger; 12 take children under 18; 7 take healthy volunteers.

This study: 14 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing rifampin in Tuberculosis, Pulmonary, or all of them as a file.
02

Study summary

This multi-centric RCT across 15 sites in India, tries to evaluates two strategies in order to improve treatment outcomes and reduce recurrences among persons with drug sensitive pulmonary TB (i) Usage of High dose Rifampicin (25mg/kg) given either for 2 months or for 6 months along with other first line anti-TB drugs (ii) Addition of a Fluoroquinolone along with high dose rifampicin to reduce the treatment duration from 6 months to 4 months.

Read the detailed description

Trail participants will be monitored for Adverse Drug reactions and clinical and radiological progress weekly during intensive phase and monthly during 1st year follow up and once in 3 months till end of follow up(30th month)

03

Conditions studied

  • Tuberculosis, Pulmonary, Drug Sensitive

Browse trials for

Keywords

  • High-dose Rifampicin
  • Pulmonary tuberculosis
  • Levofloxacin
04

In context

Tuberculosis, Pulmonary Reclassified

320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.

This study's planned enrollment of 2,500 is above the median of 147 across 228 interventional studies indexed under Tuberculosis, Pulmonary.

Browse Tuberculosis, Pulmonary studies →

Lead sponsor

Tuberculosis Research Centre, India is the lead sponsor of 15 studies on the registry; 4 are open to participants now.

Compared within Tuberculosis, Pulmonary, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Tuberculosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
14 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals aged equal or above 14 years.
  2. Symptomatic persons with newly diagnosed sputum positive PTB - smear or NAAT should be positive for Mtb
  3. Re treatment patients who had previous one episode of microbiologically confirmed (by smear and /or NAAT) pulmonary TB and currently symptomatic and sensitive to all anti-TB drugs and quinolones
  4. If +ve, > 150 cells/mm3 and willing to take ART if not already on it with stable viremia
  5. Willing to follow the trial procedures

Exclusion criteria

Exclusion Criteria:

  1. Body weight less than 30 kg in adults
  2. Anti-TB treatment, >14 days for the current illness
  3. Known Resistance to rifampicin \& Isoniazid at baseline as evidenced by Nucleic acid Amplification test (NAAT) OR LPA
  4. Patients with serious forms of Extra-pulmonary TB
  5. Patients on ART regimens.
  6. Baseline Hepatic or renal disease as evidenced by clinical or biochemical abnormalities

    • /AST> 2.5 times withTotal >2 mg/dl or isolated ALT/AST >5 times ULN (Hy's law criteria)
    • Serum Creatinine >1.2 mg/dl.
  7. Pregnant or lactating mothers
  8. Patients who are seriously ill including symptoms like pneumothorax or hemoptysis with hemodynamic instability
  9. Patients with h/o of concomitant medications which may interfere with study drugs
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,500 participants (estimated)

Study arms

  • Experimental
    2H R25 ZE /4 H R10 E

    Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily conventional dose of Rifampicin(10mg), Isoniazid, and Ethambutol

    Drug: High dose Rifampicin (25mg/Kg)

  • Experimental
    2 H R25 ZE/ 4 H R25 E

    Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily treatment with high dose Rifampicin (25mg/kg), Isoniazid, and Ethambutol

    Drug: High dose Rifampicin (25mg/Kg)

  • Experimental
    2 H R25 ZE L/2 H R25 E L

    Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, Ethambutol and Levofloxacin (750/1000mg) Continuation Phase: Two months of daily high dose Rifampicin (25mg/kg), Isoniazid, Ethambutol and Levofloxacin.

    Drug: High dose Rifamipicn (25mg/Kg) & Levofloxacin

  • Active comparator
    2 H R10 ZE /4H R10 E

    Intensive Phase: Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol Continuation Phase: Four months of Rifampicin, Isoniazid, and Ethambutol

    Drug: Standard 6-month treatment regimen

Interventions

  • DrugStandard 6-month treatment regimen

    Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol and Four months of Rifampicin, Isoniazid, and Ethambutol

  • DrugHigh dose Rifampicin (25mg/Kg)

    Drug page: Rifampin

    Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs.

  • DrugHigh dose Rifampicin (25mg/Kg)

    Drug page: Rifampin

    Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs.

  • DrugHigh dose Rifamipicn (25mg/Kg) & Levofloxacin

    Usage of High dose Rifampicin and Levofloxacin for 4 months along with other first line anti-TB drugs.

07

What researchers measure

Primary outcomes

  1. Proportion of patients cured and disease (recurrence) free and alive at 18 months post randomization

    Time frame: Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization

Secondary outcomes

  1. Proportion of patients with grade 3 or 4 adverse drug reactions.

    Time frame: Through treatment completion, an average of 24 weeks

  2. The proportion of PTB patients who require permanent change of high dose regimen to standard regimen due to adverse events

    Time frame: Through treatment completion, an average of 24 weeks

  3. The proportion of PTB patients -with smear & culture conversion at end of 2 months & at end of treatment -with radiological clearance at 2 months & at end of treatment

    Time frame: At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.

  4. The proportion of patients with drug interactions between the high dose Rifampicin & other first line anti-TB drugs & concomitant medications

    Time frame: At 1st Month

  5. The cost effectiveness of different treatment regimens

    Direct and indirect costs incurred by patient, health system and to identify the factors contributing to the cost in the management of TB.

    Time frame: Through treatment completion, an average of 24 weeks

08

Study locations

8 of 15 sites recruiting
  • All India Institute of Medical Sciences(AIIMS), Mangalagiri
    Guntur, Andhra Pradesh 522503, India
    Recruiting
  • All India Institute of Medical Sciences, Guwahati
    Guwahati, Assam 781101, India
    Active, not recruiting

    Not enrolling at this site.

  • Govt. PDU Medical College
    Rajkot, Gujarat 360001, India
    Not yet recruiting
  • Govt. Medical College and NCH
    Surat, Gujarat 395001, India
    Active, not recruiting

    Not enrolling at this site.

  • Grant Govt. Medical College & Sir JJ Group of Hospitals
    Mumbai, Maharashtra 400008, India
    Recruiting
  • All India Institute Of Medical Sciences, Nagpur
    Nagpur, Maharashtra, India
    Not yet recruiting
  • North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)
    Shillong, Meghālaya 793018, India
    Recruiting
  • National Institute of TB and Respiratory Diseases
    New Delhi, National Capital Territory of Delhi 110030, India
    Not yet recruiting
  • Post Graduate Institute of Medical Education & Research, Capital Hospital
    Bhubaneswar, Odisha 751001, India
    Active, not recruiting

    Not enrolling at this site.

  • All India Institute of Medical Sciences (AIIMS), Bhubaneswar
    Bhubaneswar, Odisha 751019, India
    Active, not recruiting

    Not enrolling at this site.

  • ICMR - National Institute for Research in Tuberculosis
    Chennai, Tamil Nadu 600031, India
    Recruiting
    • Dr PK Bhavani, MBBS., MPH., PGDBEME · Contactbhavani.pk@icmr.gov.in · 044 2836 9537
    • Dr G Narendran, MBBS., DNB., DTRD., FRCP., · Contactnarendra.ng@icmr.gov.in · 044 2836 9518
    • Dr PK Bhavani, MBBS., MPH., PGDBEME · Principal investigator
    • Dr G Narendran, MBBS., DNB., DTRD., FRCP., · Principal investigator
    • Dr R Balaji, MBBS., MD., · Sub investigator
  • Govt. General and Chest Hospital, Osmania Medical College
    Hyderabad, Telangana 500038, India
    Recruiting
  • Sarojini Naidu Medical College
    Agra, Uttar Pradesh 282002, India
    Recruiting
  • Moti Lal Nehru Medical College
    Allahābād, Uttar Pradesh 211002, India
    Recruiting
  • King George Medical University
    Lucknow, Uttar Pradesh 226003, India
    Recruiting
09

References and documents

Publications

  • Kannabiran BP, Arthanari J, Bhaskar A, Narayanan MKS, Inbaraj LR. Efficacy & safety of high-dose rifampicin in pulmonary tuberculosis: A systematic review & meta-analysis. Indian J Med Res. 2025 May;161(5):449-460. doi: 10.25259/IJMR_1673_2024. PubMed 40844096 ↗
  • Perumal Kannabiran B, Palaniappan NA, Manoharan T, Paramasivam PK, Saini JK, Ansari MS, Jayabal L, Aggarwal AN, Garg R, Subramanyam B, Thakur D, Pantula S, P M R, Gs V, Natarajan S, Ammayappan RK, Manpreet B, Ganesan M, Angamuthu D, Chinnaiyan P, Singh M, Chandrasekaran P, Swaminathan S. Safety and Efficacy of 25 mg/kg and 35 mg/kg vs 10 mg/kg Rifampicin in Pulmonary TB: A Phase IIb Randomized Controlled Trial. Open Forum Infect Dis. 2024 Feb 2;11(3):ofae034. doi: 10.1093/ofid/ofae034. eCollection 2024 Mar. PubMed 38444824 ↗

Individual participant data

Plan to share: Yes

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Dec 2028, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 18, 2026
StartActual
Jun 6, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07947056
Lead sponsor
Tuberculosis Research Centre, India
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Jun 6, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Dr PK Bhavani, MBBS., MPH., PGDBEME
Contact
bhavani.pk@icmr.gov.in
044 2836 9537
Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
Contact
narendra.ng@icmr.gov.in
044 2836 9518
Dr PK Bhavani, MBBS., MPH., PGDBEME
principal investigator · ICMR - National Institute for Research in Tuberculosis
Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
principal investigator · ICMR - National Institute for Research in Tuberculosis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifampin

Start the discussion